Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes

Author(s): Teresa Salvatore, Ornella Carbonara, Domenico Cozzolino, Roberto Torella, Ferdinando Carlo Sasso.

Journal Name: Current Diabetes Reviews

Volume 3 , Issue 1 , 2007

Submit Manuscript
Submit Proposal


Glucagon-like peptide-1 (GLP-1) may contribute to the decreased incretin effect characterizing type 2 diabetes. Multiple actions other than insulin secretion stimulation give to GLP-1 a highly desirable profile for an antidiabetic agent. To overcome the need for continuous infusion of the native compound, which is rapidly degraded by dimetyl peptidil peptidase-IV (DPP-IV), analogues with low affinity for this protease have been developed. A second major strategy is represented by DPP-IV inhibitors that act to increase endogenous GLP-1. On the basis of the promising results in clinical trials, the incretin-based therapy may offer an useful option for diabetes management.

Keywords: Incretin effect, Glucagon-like peptide-1, Type 2 diabetes, GLP-1R agonists, DPP-IV inhibitors

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [15 - 23]
Pages: 9
DOI: 10.2174/157339907779802076

Article Metrics

PDF: 11